Circulating dipeptidyl peptidase-3 at admission is associated with circulatory failure, acute kidney injury and death in severely ill burn patients.
Acute kidney injury
Biomarkers
Burn patients
Dipeptidyl peptidase-3
Mortality
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
22 04 2020
22 04 2020
Historique:
received:
20
02
2020
accepted:
13
04
2020
entrez:
24
4
2020
pubmed:
24
4
2020
medline:
1
12
2020
Statut:
epublish
Résumé
Dipeptidyl peptidase-3 (DPP3) is a metallopeptidase which cleaves bioactive peptides, notably angiotensin II, and is involved in inflammation regulation. DPP3 has been proposed to be a myocardial depressant factor and to be involved in circulatory failure in acute illnesses, possibly due to angiotensin II cleavage. In this study, we evaluated the association between plasmatic DPP3 level and outcome (mortality and hemodynamic failure) in severely ill burn patients. In this biomarker analysis of a prospective cohort study, we included severely ill adult burn patients in two tertiary burn intensive care units. DPP3 was measured at admission (DPP3 One hundred and eleven consecutive patients were enrolled. The median age was 48 (32.5-63) years, with a median total body surface area burned of 35% (25-53.5) and Abbreviated Burn Severity Index (ABSI) of 8 (7-11). Ninety-day mortality was 32%. The median DPP3 Plasma DPP3 concentration at admission was associated with an increased risk of death, circulatory failure, and AKI in severely burned patients. Whether DPP3 plasma levels could identify patients who would respond to alternative hemodynamic support strategies, such as intravenous angiotensin II, should be explored.
Sections du résumé
BACKGROUND
Dipeptidyl peptidase-3 (DPP3) is a metallopeptidase which cleaves bioactive peptides, notably angiotensin II, and is involved in inflammation regulation. DPP3 has been proposed to be a myocardial depressant factor and to be involved in circulatory failure in acute illnesses, possibly due to angiotensin II cleavage. In this study, we evaluated the association between plasmatic DPP3 level and outcome (mortality and hemodynamic failure) in severely ill burn patients.
METHODS
In this biomarker analysis of a prospective cohort study, we included severely ill adult burn patients in two tertiary burn intensive care units. DPP3 was measured at admission (DPP3
RESULTS
One hundred and eleven consecutive patients were enrolled. The median age was 48 (32.5-63) years, with a median total body surface area burned of 35% (25-53.5) and Abbreviated Burn Severity Index (ABSI) of 8 (7-11). Ninety-day mortality was 32%. The median DPP3
CONCLUSIONS
Plasma DPP3 concentration at admission was associated with an increased risk of death, circulatory failure, and AKI in severely burned patients. Whether DPP3 plasma levels could identify patients who would respond to alternative hemodynamic support strategies, such as intravenous angiotensin II, should be explored.
Identifiants
pubmed: 32321571
doi: 10.1186/s13054-020-02888-5
pii: 10.1186/s13054-020-02888-5
pmc: PMC7178561
doi:
Substances chimiques
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
EC 3.4.14.-
DPP3 protein, human
EC 3.4.14.4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
168Subventions
Organisme : Union des Blessés de la Face et de la Tête
ID : 2012
Pays : International
Références
Curr Opin Crit Care. 2018 Aug;24(4):277-285
pubmed: 29877879
Crit Care. 2013 Feb 04;17(1):204
pubmed: 23394211
J Appl Lab Med. 2019 May;3(6):943-953
pubmed: 31639686
Anesthesiology. 2018 Sep;129(3):583-589
pubmed: 29958240
Eur J Heart Fail. 2020 Feb;22(2):279-286
pubmed: 31472039
N Engl J Med. 2019 Jun 13;380(24):2349-2359
pubmed: 31189038
N Engl J Med. 2017 Aug 3;377(5):419-430
pubmed: 28528561
Intensive Care Med. 2015 Jun;41(6):1107-9
pubmed: 25573501
Ann Intensive Care. 2016 Dec;6(1):87
pubmed: 27620877
Crit Care Med. 2015 Apr;43(4):808-15
pubmed: 25559438
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Ann Surg. 1949 Aug;130(2):160-73
pubmed: 17859418
Anesth Analg. 2020 Jan;130(1):15-30
pubmed: 31348056
Ann Emerg Med. 1982 May;11(5):260-2
pubmed: 7073049
Am Heart J. 1982 Sep;104(3):603-6
pubmed: 7113901
Burns. 2008 Aug;34(5):603-9
pubmed: 18378089
Histochem J. 2001 Sep-Oct;33(9-10):511-21
pubmed: 12005022
Hypertension. 2016 Sep;68(3):630-41
pubmed: 27456521
J Crit Care. 2015 Oct;30(5):975-81
pubmed: 26015150
Mem Inst Oswaldo Cruz. 2005 Mar;100 Suppl 1:105-6
pubmed: 15962106
Eur J Heart Fail. 2020 Feb;22(2):290-299
pubmed: 31472040
Shock. 2019 Feb;51(2):153-160
pubmed: 29561390
Lancet. 2019 Nov 23;394(10212):1949-1964
pubmed: 31777389
FEBS J. 2011 Sep;278(18):3256-76
pubmed: 21794094